A registered direct offering is a sale of already-registered shares by a public company directly to a small group of institutional or accredited investors, brokered by a placement agent rather than underwritten. Because the shares come off an effective shelf registration, buyers receive freely tradable stock at closing, and the deal can be marketed confidentially and priced in a single evening. Companies in healthcare, technology, and other capital-intensive sectors lean on the structure because it closes quickly, skips the roadshow of a traditional follow-on, and generally causes less trading disruption than a broadly marketed public offering.
How the Transaction Is Structured
The setup is simple in outline. A public company with an effective shelf registration on Form S-3 sells shares off that shelf to a handful of buyers, usually hedge funds, mutual funds, or other institutions. A placement agent, typically an investment bank, brokers the transaction but does not buy the shares itself. The agent works on a best-efforts basis, meaning it tries to find buyers but does not guarantee the offering will sell out.1Securities and Exchange Commission. HeartBeam, Inc. Placement Agency Agreement That is the key contrast with a traditional underwritten deal, where the underwriter purchases all the shares from the issuer and resells them, absorbing the inventory risk.
Legally the transaction is a public offering because the securities are registered with the SEC, but the distribution behaves more like a private sale. The company and placement agent quietly approach a targeted list of investors, negotiate a price, and only announce the deal after terms are locked in. Shares are priced at a discount to the current market price to draw buyers. Academic work on these transactions has found median offer price discounts around 10%, with the range varying by company size and market conditions.
Placement agent fees commonly run between 5% and 8% of gross proceeds. Actual filed agreements show fees at 6.8% and 8%, sometimes with reduced rates for investors the issuer sources on its own.1Securities and Exchange Commission. HeartBeam, Inc. Placement Agency Agreement That is generally lower than the 7% gross spread typical of an IPO. Some agents also take warrants as part of their compensation.
The companies that use this structure most often are small-cap and micro-cap issuers in healthcare, technology, industrials, and financial services. They burn cash, need to return to the capital markets frequently, and often live with the kind of stock price volatility that makes a weeks-long marketed follow-on impractical. Larger companies with stable share prices and deep institutional followings usually have less need for the structure and can run traditional follow-ons or tap the debt markets instead.
Form S-3 Eligibility and the Baby Shelf Rule
The gate to running one of these offerings is Form S-3. To use it, a company must have filed all required SEC reports on time for at least the prior twelve months.2eCFR. 17 CFR 239.13 – Form S-3 The shelf registration is filed under Rule 415, which permits securities to be offered on a delayed or continuous basis.3eCFR. 17 CFR 230.415 – Delayed or Continuous Offering and Sale of Securities Once effective, the shelf lasts three years, and the company can sell off it at any time without filing a fresh registration statement for each deal.
How much a company can sell depends on its public float, meaning the market value of shares held by non-affiliates. If the float is above $75 million, the issuer can sell as much as market demand and board authorization allow.2eCFR. 17 CFR 239.13 – Form S-3
Smaller reporting companies with floats under $75 million run into the baby shelf limitation. They can sell no more than one-third of their public float in primary offerings over any rolling twelve-month period.2eCFR. 17 CFR 239.13 – Form S-3 The rule is designed to keep smaller companies from flooding the market with new shares and crushing existing holders. For an issuer with a $30 million float, the twelve-month primary shelf ceiling is roughly $10 million. Working around this cap is one of the harder parts of capital planning at small public companies.
The Offering Process
Wall-Crossing and Confidential Marketing
Before anything becomes public, the placement agent contacts potential investors confidentially in what the market calls wall-crossing. The idea is to bring investors over the wall, sharing material non-public information about the planned offering. Once wall-crossed, those investors cannot trade the company’s stock until the deal is announced.
This obviously bumps up against selective disclosure concerns, but Regulation FD carves out an exemption for communications made in connection with a registered securities offering. Oral communications with prospective investors after the registration statement is on file are permitted under that exemption.4eCFR. 17 CFR 243.100 – General Rule Regarding Selective Disclosure The company and its agent still have to run the process cleanly: investors should explicitly consent to receiving the confidential information and acknowledge the trading restriction. Some institutions decline wall-crossing as a matter of policy, so experienced placement agents know in advance who will engage.
Pricing and Announcement
Pricing usually happens in a single evening. The agent gauges interest, negotiates a price at a discount to that day’s closing level, and locks in commitments. Once investors sign the securities purchase agreement, the company files a prospectus supplement, known as a 424(b) filing, through EDGAR and issues a press release announcing the deal.5eCFR. 17 CFR 230.424 – Filing of Prospectuses, Number of Copies The supplement carries the deal-specific terms: price per share, share count, proceeds, placement agent identity, use of proceeds, and any warrants. Together with the base prospectus already on file, it forms the complete disclosure package. The entire marketing and pricing sequence often takes less than 24 hours, which is the point of the structure.
Settlement
As of May 2024, most securities transactions settle T+1, one business day after the trade date, following SEC amendments that shortened the cycle from T+2.6U.S. Securities and Exchange Commission. Shortening the Securities Transaction Settlement Cycle Closings on these offerings track that timeline, with the specific closing date negotiated in the purchase agreement. At closing, shares move electronically through the Depository Trust Company against the investors’ cash, and the company receives its proceeds.
Registered Direct Offering vs. PIPE
The comparison worth knowing is with a PIPE, or Private Investment in Public Equity, since both involve selling shares to a narrow group of investors rather than to the broad market. The legal mechanics diverge in ways that matter.
- Registration timing. In a registered direct offering, the shares are already registered on an effective shelf before the sale, so investors receive freely tradable stock at closing. In a PIPE, the company sells unregistered shares under a private placement exemption and then files a resale registration statement afterward, typically within 30 to 60 days. Until that resale registration goes effective, PIPE investors hold restricted stock.
- Investor liquidity. This is the practical difference. RDO investors can sell immediately. PIPE investors may be locked in for months waiting on the resale registration, which is why they demand a steeper discount.
- Pricing. Because the RDO investor gets immediate liquidity, pricing tends to be better for the issuer than in a PIPE.
- Cost and speed. RDOs skip the separate resale registration a PIPE requires. An RDO can close in days with experienced institutional buyers. A PIPE, with its two-step registration, can stretch for months.
- Eligibility. The RDO requires an effective S-3 shelf. A PIPE has no such prerequisite, since the initial sale relies on a registration exemption, so it remains available to companies that cannot qualify for Form S-3.
For companies that qualify for Form S-3, the RDO is almost always the preferred route. PIPEs remain the fallback for issuers that lack an effective shelf or need to sell securities that are not yet registered.
Warrants as Part of the Deal
Many of these offerings, especially those by smaller companies, bundle warrants alongside the common stock. A warrant gives the investor the right to buy additional shares at a set exercise price during a defined period. For the investor, it adds upside if the stock recovers above that price. For the issuer, attaching warrants can mean accepting a smaller discount on the common stock portion of the deal, because the warrant component adds value to the overall package.
The cost is more dilution. When warrants get exercised, new shares are issued, on top of the shares sold in the offering itself. Some issuers structure at-market offerings that pair shares with warrants rather than discounting the common stock, using the warrants to close the gap between what investors want and what the company will give up on price. Warrant terms vary widely. Exercise prices may be set at or above the offering price, and expirations can run from a few years out to five years or more. The specific terms sit in the prospectus supplement.
Stock Price Impact and Dilution
Announcing one of these offerings almost always pushes the stock down. Academic research across thousands of transactions found the average announcement-day drop was roughly 7%, with a median decline of similar size. Part of that reflects the offering discount being priced in. Part of it reflects the signal that the company needs cash, which the market rarely reads as good news. Even so, the market disruption tends to be smaller than in a fully marketed follow-on, where a longer marketing window creates more sustained selling pressure. The confidential process compresses the volatility into a shorter window.
Dilution is a matter of arithmetic. If a company has 10 million shares outstanding and sells 2 million new ones, existing holders own a smaller slice. Add warrants and the potential dilution grows further. Dilution concerns are sharpest at companies operating under the baby shelf cap, since a smaller float means any new issuance is a larger proportional bump in shares outstanding. If you hold stock in a company that announces one of these deals, the figures to check in the prospectus supplement are the number of new shares, any warrants attached, the warrant exercise price, and how the total stacks up against the existing share count.